PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

Terrence F. Meehan(European Bioinformatics Institute), Nathalie Conte(European Bioinformatics Institute), Theodore C. Goldstein, Giorgio Inghirami(Cornell University), Mark A. Murakami(Dana-Farber Cancer Institute), Sebastian Brabetz(German Cancer Research Center), Zhiping Gu(Northrop Grumman (United States)), Jeffrey A. Wiser(Northrop Grumman (United States)), Patrick Dunn(Northrop Grumman (United States)), Dale A. Begley(Jackson Laboratory), Debra M. Krupke(Jackson Laboratory), Andrea Bertotti(Candiolo Cancer Institute), Alejandra Bruna(Cancer Research UK Cambridge Center), Matthew Brush(Oregon Health & Science University), Annette T. Byrne(Royal College of Surgeons in Ireland), Carlos Caldas(Cancer Research UK Cambridge Center), Amanda L. Christie(Dana-Farber Cancer Institute), Dominic A. Clark(European Bioinformatics Institute), Heidi Dowst(Children's Cancer Center), Jonathan R. Dry(AstraZeneca (United States)), James H. Doroshow(National Cancer Institute), Olivier Duchamp(Immersion (France)), Yvonne A. Evrard(Leidos (United States)), Stéphane Ferretti(Novartis (Switzerland)), Kristopher K. Frese(University of Manchester), Neal Goodwin(Champions Oncology (United States)), Danielle M. Greenawalt(Bristol-Myers Squibb (Germany)), Melissa Haendel(Oregon Health & Science University), Els Hermans(KU Leuven), Peter J. Houghton(The University of Texas at San Antonio Health Science Center), Jos Jonkers(Dutch Cancer Society), Kristel Kemper(Dutch Cancer Society), Tin Oo Khor(The University of Texas MD Anderson Cancer Center), Michael T. Lewis(Baylor College of Medicine), K. C. Kent Lloyd(University of California, Davis), Jeremy Mason(European Bioinformatics Institute), Enzo Médico(Candiolo Cancer Institute), Steven B. Neuhauser(Jackson Laboratory), James M. Olson(Fred Hutch Cancer Center), Daniel S. Peeper(Dutch Cancer Society), Oscar M. Rueda(Cancer Research UK Cambridge Center), Je Kyung Seong(Korea Institute of Science & Technology Information), Livio Trusolino(Candiolo Cancer Institute), Emilie Vinolo(Systématique, adaptation, évolution), Robert J. Wechsler‐Reya(National Foundation for Cancer Research), David M. Weinstock(Dana-Farber Cancer Institute), Alana L. Welm(Huntsman Cancer Institute), S. John Weroha(Mayo Clinic), Frédéric Amant(Dutch Cancer Society), Stefan M. Pfister(German Cancer Research Center), Marcel Kool(German Cancer Research Center), Helen Parkinson(European Bioinformatics Institute), Atul J. Butte, Carol J. Bult(Jackson Laboratory)
Cancer Research
October 31, 2017
Cited by 128Open Access
Full Text

Abstract

Abstract Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patients. The lack of robust standards for reporting on PDX models has hampered the ability of researchers to find relevant PDX models and associated data. Here we present the PDX models minimal information standard (PDX-MI) for reporting on the generation, quality assurance, and use of PDX models. PDX-MI defines the minimal information for describing the clinical attributes of a patient's tumor, the processes of implantation and passaging of tumors in a host mouse strain, quality assurance methods, and the use of PDX models in cancer research. Adherence to PDX-MI standards will facilitate accurate search results for oncology models and their associated data across distributed repository databases and promote reproducibility in research studies using these models. Cancer Res; 77(21); e62–66. ©2017 AACR.


Related Papers

No related papers found

Powered by citation graph analysis